StockNews.com Upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to Buy

StockNews.com upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning.

A number of other analysts have also issued reports on ALNY. Scotiabank lifted their target price on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 31st. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Chardan Capital reiterated a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Wells Fargo & Company lifted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a research note on Friday, March 21st. Finally, Stifel Nicolaus raised their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a report on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $315.58.

Alnylam Pharmaceuticals Trading Up 0.3 %

Shares of ALNY opened at $242.61 on Tuesday. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The stock’s 50-day moving average is $247.34 and its two-hundred day moving average is $256.23. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a market cap of $31.56 billion, a PE ratio of -111.80 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the transaction, the chief executive officer now owns 81,526 shares in the company, valued at approximately $20,802,989.42. This represents a 1.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares in the company, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 59,984 shares of company stock valued at $16,864,347 in the last 90 days. 1.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tidal Investments LLC raised its holdings in shares of Alnylam Pharmaceuticals by 75.1% in the third quarter. Tidal Investments LLC now owns 20,544 shares of the biopharmaceutical company’s stock valued at $5,650,000 after purchasing an additional 8,811 shares during the last quarter. American Trust acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $309,000. Versant Capital Management Inc increased its stake in Alnylam Pharmaceuticals by 77.6% in the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 83 shares during the last quarter. Everence Capital Management Inc. bought a new stake in Alnylam Pharmaceuticals during the 4th quarter worth about $593,000. Finally, Nordea Investment Management AB grew its holdings in shares of Alnylam Pharmaceuticals by 6.7% in the 4th quarter. Nordea Investment Management AB now owns 10,188 shares of the biopharmaceutical company’s stock valued at $2,417,000 after acquiring an additional 637 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.